Printer Friendly

Seres Therapeutics Names Kevin Horgan as Chief Medical Officer.

M2 PHARMA-October 25, 2018-Seres Therapeutics Names Kevin Horgan as Chief Medical Officer

(C)2018 M2 COMMUNICATIONS

- US-based microbiome therapeutics platform company Seres Therapeutics, Inc. (NASDAQ: MCRB) has appointed Kevin Horgan, M.D., as executive vice president and chief medical officer, the company said.

Horgan will lead Seres' clinical development, clinical operations, regulatory affairs, and medical affairs functions. Horgan will succeed Seres' outgoing CMO, Michele Trucksis, Ph.D., M.D., who will continue to provide consulting services to the company.

Over a three-decade academic and industry career, Dr. Horgan has contributed to the development and approval of multiple therapeutics across immunology and oncology indications. Most recently, Dr.

Horgan was vice president of clinical development at AstraZeneca where he led the development of combination immune-oncology programs.

He earlier co-founded Tucana Health, a microbiome diagnostics company.

Previously, Horgan held CMO roles at Soligenix and Coronado.

Prior to those roles, he was vice president of clinical immunology at Centocor during the development and approval of Remicade, Stelara and Simponi, approved for inflammatory bowel disease indications.

Seres Therapeutics, Inc. (NASDAQ: MCRB) is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.

The company's lead programme, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate ulcerative colitis.

Seres is developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. Seres is also developing SER-401 to augment the efficacy of immuno-oncology treatment.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 25, 2018
Words:305
Previous Article:Genentech's Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell...
Next Article:Opdivoin Combination with Yervoy Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters